{"product_id":"gerresheimer-business-model-canvas","title":"Gerresheimer Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer Business Model Canvas: Strategic Blueprint for Investors \u0026amp; Innovators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Gerresheimer’s business model — our in-depth Business Model Canvas unpacks value propositions, customer segments, key partnerships, and revenue streams to show how the company scales and stays competitive; ideal for investors, consultants, and entrepreneurs seeking actionable insights. Download the complete Word\/Excel canvas to benchmark, plan, and execute with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical and Biotech Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer partners with top-tier pharma firms to co-develop specialized primary packaging and delivery systems, aligning design to complex biologics and biosimilars; by end-2025 these alliances cover integrated supply-chain agreements securing \u0026gt;€400m in committed volumes and reducing lead times by 22%.\u003c\/p\u003e\n\u003cp\u003eThese collaborations drive joint R\u0026amp;D investments (≈€25m cumulative 2023–25) and shared innovation KPIs—targeting 30% faster regulatory filing readiness for partner drug-device combinations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Technology Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer partners with sensor, microelectronics and connectivity firms to build smart pens and inhalers that track adherence, cutting R\u0026amp;D time; in 2024 Gerresheimer reported digital-product sales growth of ~12% and targets connected-device launches within 12–18 months. These tech alliances let Gerresheimer avoid full in-house software stacks, lowering upfront capex and accelerating time-to-market for connected health solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Energy Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer secures high-purity quartz sand and medical-grade polymers via multi-year supply contracts—cutting input-price volatility and guaranteeing \u0026gt;30% recycled content in select lines by 2025; raw-material spend totaled ~€520m in 2024. \u003c\/p\u003e\n\u003cp\u003eBy 2025 Gerresheimer partners with renewable energy providers to source 60–80% of electricity for glass furnaces, supporting its target to halve Scope 1+2 emissions vs.2019 and lowering energy costs amid volatile fuel markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpglobal distribution relies on partners like dhl global forwarding and kuehne that handle sterile transport cold chain for prefillable syringes cutting transit contamination risk to near zero in cold-chain pharma logistics grew a market enabling gerresheimer serve\u003e50 manufacturing sites worldwide with validated handling protocols.\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eValidated cold chain capacity for 2–8°C and frozen loads\u003c\/li\u003e\n\u003cli\u003eGx uses GDP\/GMP-compliant carriers\u003c\/li\u003e\n\u003cli\u003eReal-time temperature monitoring, ASN tracking\u003c\/li\u003e\n\u003cli\u003eInsured transit minimizing damage claims\u003c\/li\u003e\n\u003cli\u003eScalable hub-and-spoke networks to 50+ sites\u003c\/li\u003e\n\n\u003c\/pglobal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Universities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration with universities keeps Gerresheimer at the cutting edge of materials and drug delivery; joint projects in 2024 led to 12 peer-reviewed papers and two pilot-coated glass vial trials that reduced leachables by 35% versus standard vials.\u003c\/p\u003e\n\u003cp\u003ePartnerships target glass coatings, biodegradable polymers, and 3D-printed components, feeding a commercialization pipeline that contributed an estimated €18m in licensing revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 papers (2024)\u003c\/li\u003e\n\u003cli\u003e35% leachables reduction\u003c\/li\u003e\n\u003cli\u003e2 pilot vial trials\u003c\/li\u003e\n\u003cli\u003e€18m licensing revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer partnerships drive €400m pharma deals, digital growth \u0026amp; 50% emissions cut\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer's key partnerships span pharma co-development (committed \u0026gt;€400m volumes by end-2025), tech partners for connected devices (digital sales +12% in 2024), secured raw-material spend ~€520m (2024), and renewable-energy contracts to source 60–80% furnace power by 2025, reducing Scope1+2 emissions ~50% vs 2019.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma alliances\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€400m committed volumes (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech partners\u003c\/td\u003e\n\u003ctd\u003eDigital sales +12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e€520m spend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewable energy\u003c\/td\u003e\n\u003ctd\u003e60–80% electricity for furnaces (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Gerresheimer detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams aligned with its medical packaging and specialty glass strategy, with SWOT-linked insights and polished visuals ideal for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Gerresheimer’s pharmaceuticals and specialty glass business model into a one-page, editable snapshot to quickly identify value drivers and operational levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Manufacturing and Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is high-volume, high-precision production of glass and plastic containment solutions across ~60 global sites, producing ~3.2 billion primary packaging units in 2024 and generating €1.4bn manufacturing revenue that year.\u003c\/p\u003e\n\u003cp\u003eIt runs advanced furnace glass blowing and multi-shot injection molding for complex drug-delivery devices, with €120m invested in automation and robotics since 2022 to hold tolerances down to microns for medical safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Drug Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer spends ~€100–130m annually on R and D for drug delivery, focusing on auto-injectors, pumps, and inhalers to boost safety, ease-of-use, and add digital tracking (RFID\/Bluetooth). By late 2025 roughly 30–40% of R and D effort targets GLP-1 therapies for obesity and diabetes, with dedicated programs for high-volume pen systems and precision-dose pumps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining rigorous QC and regulatory compliance is non-negotiable: Gerresheimer follows FDA, EMA and other authorities, supporting \u0026gt;€1.6bn 2024 revenues by preserving market access. The company runs exhaustive extractables\/leachables and container-closure integrity testing—reducing batch rejection risk below industry avg 1.5%—and sustains ISO 13485 and GMP certifications required to serve pharma clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Operations Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGerresheimer manages a global supply chain across Europe, North America and Asia, moving raw materials and finished pharma\/medical packaging to cut lead times and emissions by shifting production closer to customers; in 2024 ~58% of sales were from local production regions, trimming logistics costs and CO2 per unit.\u003c\/p\u003e\n\u003cp\u003eDemand forecasting and capacity planning use real-time ERP and AI tools to match volatile healthcare demand, keeping utilization near 85% in 2024 to avoid stockouts while limiting excess inventory.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal footprint: Europe, NA, Asia; 58% local sales (2024)\u003c\/li\u003e\n\u003cli\u003eTarget capacity utilization ~85% (2024)\u003c\/li\u003e\n\u003cli\u003eReduced lead times and CO2 per unit via regional sites\u003c\/li\u003e\n\u003cli\u003eReal-time ERP + AI demand forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Key Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGerresheimer runs high-level B2B sales targeting procurement and R and D heads at pharma firms, securing tailored solutions over standard products to win multi-year supply contracts that stabilize revenue.\u003c\/p\u003e\n\u003cp\u003eKey account managers drive consultative sales; in 2024 Gerresheimer reported ~€2.1bn revenue with ~60% from pharma\/healthcare, where top clients yield multi-year contracts averaging 3–7 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: procurement and R and D decision-makers\u003c\/li\u003e\n\u003cli\u003eApproach: consultative, customized solutions\u003c\/li\u003e\n\u003cli\u003eOutcome: multi-year contracts (3–7 years) for revenue stability\u003c\/li\u003e\n\u003cli\u003e2024 context: ~€2.1bn group revenue; ~60% pharma exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑precision pharma packaging: 3.2bn units, €1.4bn manufacturing, AI‑driven supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-volume, high-precision manufacturing of glass\/plastic pharma packaging and drug-delivery devices (≈3.2bn units, €1.4bn manufacturing revenue in 2024), plus R\u0026amp;D (~€100–130m p.a.; 30–40% on GLP‑1 by late 2025) and strict QC\/regulatory programs (ISO 13485\/GMP; batch rejection \u0026lt;1.5%) supporting global supply, AI-driven demand planning (85% utilization 2024) and consultative B2B sales securing 3–7y contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary units\u003c\/td\u003e\n\u003ctd\u003e≈3.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing rev\u003c\/td\u003e\n\u003ctd\u003e€1.4bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€2.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€100–130m p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal sales\u003c\/td\u003e\n\u003ctd\u003e58% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Gerresheimer Business Model Canvas shown here is the actual deliverable, not a mockup—it's a direct snapshot of the file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this same professional, fully editable Business Model Canvas in Word and Excel, structured and formatted exactly as previewed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749680591225,"sku":"gerresheimer-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gerresheimer-business-model-canvas.png?v=1772216842","url":"https:\/\/growthsharematrix.com\/products\/gerresheimer-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}